Efficacy of autologous adipose tissue-derived mesenchymal stem cell therapy in Duchenne muscular dystrophic patients

Not Applicable

Recruiting

Conditions: Duchenne muscular dystrophy.
Muscular dystrophy
G71.01

Registration Number: IRCT20150206020981N3

Lead Sponsor: Research Deputy of Islamic Azad University, Tehran Medical Branch

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Male

Target Recruitment: 10

Inclusion Criteria

Genetic evidence of Duchenne disease as a cause of myopathy
The patient's ability to walk is not completely lost and the use of assistive devices such as canes and walkers is not permanent.
The patient's muscle strength is decreasing
Willingness and satisfaction to participate in the study by the patient's legal guardian in decision making and willingness to participate regularly in follow-up courses

Exclusion Criteria

Advanced motor impairment leading to permanent use of crutches, walkers and wheelchairs
A history of known malignancy
History of associated genetic and non-genetic degenerative diseases
Having blood and internal diseases that increase the risk of liposuction and anesthesia required
A history of any other acute or chronic illness that, at the discretion of the clinician responsible for implementing the plan, prevents the patient from entering the study.
Insufficient volume of subcutaneous fat or the presence of concomitant injuries in the abdomen in the initial examination that make it difficult to obtain adipose tissue to prepare SVF.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Respiratory Function. Timepoint: 1, 3, 6, 9 and 12 month after injection. Method of measurement: Spirometery.;Muscular Force. Timepoint: First every 14 days to 1 month, then Every 1 month to 1 year. Method of measurement: Physical Exam.;Cardiac Function. Timepoint: 1, 3, 6, 9 and 12 month after injection. Method of measurement: Echocardiography.

Secondary Outcome Measures